Castle Biosciences Inc (CSTL) — Titan Protect Analysis

CSTL

Castle Biosciences Inc

Healthcare · ·

$21.01

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$605M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-21.44

Based on estimated future earnings — lower means cheaper

Rev Growth

-4.9%

Year-over-year revenue change

Profit Margin

-3.8%

How much profit the company keeps from each dollar of revenue

ROE

-2.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$44.00

+109% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 8 analysts covering this stock

About Castle Biosciences Inc

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to

https://castlebiosciences.com

Country: United States Employees: 942 Industry: Diagnostics & Research

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.241

Positive but modest risk-adjusted returns

Kelly Fraction

0.0205

Modest edge detected — smaller position warranted

Calmar Ratio

-0.064

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-3.7%

Historical annualised return based on price data

Max Drawdown

-57.8%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.11

Moves slightly more than the broader market

52W High

$44.28

53% below the year high

52W Low

$14.59

44% above the year low

Avg Volume

383,249

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.42

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

7.96

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

77.9%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-22.0%

Profit from core operations before interest and tax

Free Cash Flow

$13M

Positive — the business generates more cash than it spends

Revenue (TTM)

$340M

Total revenue over the last 12 months

Net Income

$-12,832,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$52.00

Target Median

$44.00

Target Low

$35.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go